Metastatic Urothelial Cancer Completed Phase 2 Trials for Avelumab (DB11945)

IndicationStatusPhase
DBCOND0066157 (Metastatic Urothelial Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03390595Avelumab Plus Carboplatin-gemcitabine in Urothelial CarcinomaTreatment